LEADER 05458nam 2200649 a 450 001 9910465388103321 005 20200520144314.0 010 $a1-299-24223-5 010 $a1-118-57054-5 035 $a(CKB)2560000000098549 035 $a(EBL)1132871 035 $a(OCoLC)824890409 035 $a(SSID)ssj0000833718 035 $a(PQKBManifestationID)11411975 035 $a(PQKBTitleCode)TC0000833718 035 $a(PQKBWorkID)10936316 035 $a(PQKB)10814770 035 $a(MiAaPQ)EBC1132871 035 $a(Au-PeEL)EBL1132871 035 $a(CaPaEBR)ebr10667387 035 $a(CaONFJC)MIL455473 035 $a(EXLCZ)992560000000098549 100 $a20130116d2013 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aNanoparticulate drug delivery systems$b[electronic resource] $estrategies, technologies, and applications /$fedited by Yoon Yeo 210 $aHoboken, N.J. $cWiley$d2013 215 $a1 online resource (326 p.) 300 $aDescription based upon print version of record. 311 $a1-118-14887-8 320 $aIncludes bibliographical references and index. 327 $aNanoparticulate Drug Delivery Systems: Strategies, Technologies, and Applications; Contents; Preface; Contributors; 1 Tumor-Targeted Nanoparticles: State-of-the-Art and Remaining Challenges; 1.1 INTRODUCTION; 1.2 FUNCTIONS OF NANOPARTICLES; 1.3 TUMOR-TARGETED NANOPARTICLES; 1.3.1 Passive Targeting; 1.3.2 Active Targeting; 1.3.3 Target-Activated Systems; 1.4 REMAINING CHALLENGES IN THE DEVELOPMENT OF TUMOR-TARGETED NANOPARTICLES; 1.4.1 NP Stability; 1.4.2 Heterogeneous Tumor Vasculature; 1.4.3 NP Distribution in Tumors; 1.4.4 Regulatory Considerations; 1.5 FUTURE PERSPECTIVES 327 $a1.5.1 In Vitro Models1.5.2 In Vivo Models; 1.5.3 New Targets; 1.5.4 New Therapeutic Agents; Acknowledgments; REFERENCES; 2 Applications of Ligand-Engineered Nanomedicines; 2.1 INTRODUCTION; 2.1.1 Nanoparticulate Drug Delivery; 2.1.2 Engineered Nanoparticulate Drug Delivery; 2.2 LIGAND-MEDIATED DELIVERY; 2.2.1 Antibodies; 2.2.2 Peptides and Proteins; 2.2.3 Sugars and Polysaccharides; 2.2.4 Small Molecule Chemicals; 2.3 CURRENT CHALLENGES IN CLINICAL DEVELOPMENT OF LIGAND-MODIFIED NANOMEDICINE; 2.3.1 Nonclinical and Clinical Studies; 2.3.2 Challenges and Future Perspectives; 2.4 CONCLUSIONS 327 $aAcknowledgmentsREFERENCES; 3 Lipid Nanoparticles for the Delivery of Nucleic Acids; 3.1 INTRODUCTION; 3.2 BARRIERS TO SYSTEMIC GENE DELIVERY; 3.2.1 Extracellular Barriers; 3.2.2 Intracellular Barriers; 3.3 COMPONENTS OF LNPs; 3.3.1 Cationic Lipid; 3.3.2 Neutral Lipid; 3.3.3 Anionic Lipid; 3.3.4 PEG-Lipid Conjugates; 3.4 FORMULATIONS OF THE LNP FOR NUCLEIC ACIDS ENCAPSULATION; 3.4.1 Self-Assembly; 3.4.2 Detergent Dialysis; 3.4.3 Nanometric Calcium Phosphate/siRNA Precipitation; 3.5 ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACIDS WITH LNPs; 3.5.1 Brain-Targeted Delivery; 3.5.2 Liver-Targeted Delivery 327 $a3.5.3 Lung-Targeted Delivery3.5.4 Kidney-Targeted Delivery; 3.6 CURRENT CHALLENGES TO THE DEVELOPMENT OF LNPs; 3.7 FUTURE PERSPECTIVES; Acknowledgments; REFERENCES; 4 Photosensitive Liposomes as Potential Targeted Therapeutic Agents; 4.1 INTRODUCTION; 4.2 EXPERIMENTAL PROCEDURES; 4.2.1 Materials; 4.2.2 Synthesis of 1-Bromo-3-hexadecylthiobenzene (1); 4.2.3 Synthesis of 9-[3-Hexadecylthiophenyl] anthracene (2); 4.2.4 Synthesis of 9-[3-Hexadecyl-3'-cyanobenzylsulfonium] phenylanthracene Trifluoromethanesulfonate (C16-An-PAG) (3); 4.2.5 Liposome Preparation; 4.2.6 Dynamic Light Scattering 327 $a4.2.7 Photoexcitation Method4.2.8 Calcium Ion Release Assay; 4.2.9 Negative Stain Transmission Electron Microscopy; 4.2.10 Animal Studies; 4.3 RESULTS AND DISCUSSION; 4.3.1 DOPE:LysoPlsC Liposomes Using C16-An-PAG as a Photosensitizer; 4.3.2 PPlsC Liposomes Using Bchl a as a Photosensitizer; 4.3.3 Folate Receptor (FR)-Targeted DPPlsC Liposomes Using AlPcS4-4 as a Photosensitizer; 4.4 CONCLUSIONS; 4.5 PROSPECTS FOR LIGHT-ACTIVATED LIPOSOMAL DRUG DELIVERY; Acknowledgments; REFERENCES; 5 Multifunctional Dendritic Nanocarriers: The Architecture and Applications in Targeted Drug Delivery 327 $a5.1 RECENT ADVANCES IN DENDRITIC NANOMATERIALS 330 $a"The use of nanoparticles to deliver drugs to specific cells has substantially increased. This guide offers a thorough, up-to-date reference on nanotechnologies for drug delivery, frankly discussing challenges and limitations with nanoparticulate drug delivery systems. After discussing strategies to further develop these systems, chapters focus on applications like nanoparticles for topical drug delivery and nanomedicine toxicology, along with new techniques and methodologies like NanoCrystal. This up-to-date book offers an invaluable reference to any pharmaceutical researcher interested in nanomedicine"--$cProvided by publisher. 606 $aNanoparticles 606 $aDrug delivery systems 606 $aPharmaceutical biotechnology 608 $aElectronic books. 615 0$aNanoparticles. 615 0$aDrug delivery systems. 615 0$aPharmaceutical biotechnology. 676 $a615.1/9 701 $aYeo$b Yoon$0919520 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910465388103321 996 $aNanoparticulate drug delivery systems$92062391 997 $aUNINA